Generics North America (NAFTA) Industry Guide 2017-2021
February 2018
66
About the Report
About the Report
Generics North America (NAFTA) Industry Guide 2017-2021
Summary
The NAFTA Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Synopsis
Essential resource for top-line data and analysis covering the NAFTA generics market. Includes market size data, textual and graphical analysis of market growth trends and leading companies.
Key Highlights
The North American Free Trade Agreement (NAFTA) is a trade agreement between the countries in North America: the US, Canada and Mexico. The generics industry within the NAFTA countries had a total market value of USD1,11,669.7 million in 2016.The Mexico was the fastest growing country, with a CAGR of 14.3% over the 2012-16 period.
Within the generics industry, the US is the leading country among the NAFTA bloc, with market revenues of USD1,01,790.0 million in 2016. This was followed by Mexico and Canada, with a value of USD5,430.1 and USD4,449.6 million, respectively.
The US is expected to lead the generics industry in the NAFTA bloc, with a value of USD1,48,130.6 million in 2021, followed by Mexico and Canada with expected values of USD10,769.6 and USD6,409.3 million, respectively.
Scope
Save time carrying out entry-level research by identifying the size, growth, and leading players in the NAFTA generics market
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the NAFTA generics market
Leading company profiles reveal details of key generics market players' NAFTA operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the NAFTA generics market with five year forecasts by both value and volume
Compares data from the US, Canada and Mexico, alongside individual chapters on each country
Reasons to buy
What was the size of the NAFTA generics market by value in 2016?
What will be the size of the NAFTA generics market in 2021?
What factors are affecting the strength of competition in the NAFTA generics market?
How has the market performed over the last five years?
How large is the NAFTA generics market in relation to its regional counterparts?
Products
Table of Contents
Table of Contents
Table of Contents
Introduction
What is this report about?
Who is the target reader?
How to use this report
Definitions
NAFTA Generics
Industry Outlook
Generics in Canada
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Mexico
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in The United States 40
Market Overview 40
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Company Profiles
Leading Companies
Appendix
Methodology
About MarketLine
List of Figure
List of Figures
Figure 1: NAFTA countries generics industry, revenue (USDm), 2012-21
Figure 2: NAFTA countries generics industry, revenue (USDm), 2012-16
Figure 3: NAFTA countries generics industry forecast, revenue (USDm), 2016-21
Figure 4: Canada generics market value: USD million, 2012-16
Figure 5: Canada generics market volume: % of total pharma volume, 2012-16
Figure 6: Canada generics market geography segmentation: % share, by value, 2016
Figure 7: Canada generics market value forecast: USD million, 2016-21
Figure 8: Canada generics market volume forecast: % of total pharma volume, 2016-21
Figure 9: Forces driving competition in the generics market in Canada, 2016
Figure 10: Drivers of buyer power in the generics market in Canada, 2016
Figure 11: Drivers of supplier power in the generics market in Canada, 2016
Figure 12: Factors influencing the likelihood of new entrants in the generics market in Canada, 2016
Figure 13: Factors influencing the threat of substitutes in the generics market in Canada, 2016
Figure 14: Drivers of degree of rivalry in the generics market in Canada, 2016
Figure 15: Mexico generics market value: USD million, 2012-16
Figure 16: Mexico generics market volume: % of total pharma volume, 2012-16
Figure 17: Mexico generics market geography segmentation: % share, by value, 2016
Figure 18: Mexico generics market value forecast: USD million, 2016-21
Figure 19: Mexico generics market volume forecast: % of total pharma volume, 2016-21
Figure 20: Forces driving competition in the generics market in Mexico, 2016
Figure 21: Drivers of buyer power in the generics market in Mexico, 2016
Figure 22: Drivers of supplier power in the generics market in Mexico, 2016
Figure 23: Factors influencing the likelihood of new entrants in the generics market in Mexico, 2016
Figure 24: Factors influencing the threat of substitutes in the generics market in Mexico, 2016
Figure 25: Drivers of degree of rivalry in the generics market in Mexico, 2016
Figure 26: United States generics market value: USD billion, 2012-16
Figure 27: United States generics market volume: % of total pharma volume, 2012-16
Figure 28: United States generics market geography segmentation: % share, by value, 2016
Figure 29: United States generics market value forecast: USD billion, 2016-21
Figure 30: United States generics market volume forecast: % of total pharma volume, 2016-21
Figure 31: Forces driving competition in the generics market in the United States, 2016
Figure 32: Drivers of buyer power in the generics market in the United States, 2016
Figure 33: Drivers of supplier power in the generics market in the United States, 2016
Figure 34: Factors influencing the likelihood of new entrants in the generics market in the United States, 2016
Figure 35: Factors influencing the threat of substitutes in the generics market in the United States, 2016
Figure 36: Drivers of degree of rivalry in the generics market in the United States, 2016
Figure 37: Mylan N.V.: revenues & profitability
Figure 38: Mylan N.V.: assets & liabilities
Figure 39: Novartis AG: revenues & profitability
Figure 40: Novartis AG: assets & liabilities
Figure 41: Teva Pharmaceutical Industries Limited: revenues & profitability
Figure 42: Teva Pharmaceutical Industries Limited: assets & liabilities
List of Table
List of Tables
Table 1: NAFTA countries generics industry, revenue (USDm), 2012-21
Table 2: NAFTA countries generics industry, revenue (USDm), 2012-16
Table 3: NAFTA countries generics industry forecast, revenue (USDm), 2016-21
Table 4: Canada generics market value: USD million, 2012-16
Table 5: Canada generics market volume: % of total pharma volume, 2012-16
Table 6: Canada generics market geography segmentation: USD million, 2016
Table 7: Canada generics market value forecast: USD million, 2016-21
Table 8: Canada generics market volume forecast: % of total pharma volume, 2016-21
Table 31: Canada size of population (million), 2012-16
Table 32: Canada gdp (constant 2005 prices, USD billion), 2012-16
Table 33: Canada gdp (current prices, USD billion), 2012-16
Table 34: Canada inflation, 2012-16
Table 35: Canada consumer price index (absolute), 2012-16
Table 36: Canada exchange rate, 2012-16
Table 9: Mexico generics market value: USD million, 2012-16
Table 10: Mexico generics market volume: % of total pharma volume, 2012-16
Table 11: Mexico generics market geography segmentation: USD million, 2016
Table 12: Mexico generics market value forecast: USD million, 2016-21
Table 13: Mexico generics market volume forecast: % of total pharma volume, 2016-21
Table 14: Mexico size of population (million), 2012-16
Table 15: Mexico gdp (constant 2005 prices, USD billion), 2012-16
Table 16: Mexico gdp (current prices, USD billion), 2012-16
Table 17: Mexico inflation, 2012-16
Table 18: Mexico consumer price index (absolute), 2012-16
Table 19: Mexico exchange rate, 2012-16
Table 20: United States generics market value: USD billion, 2012-16
Table 21: United States generics market volume: % of total pharma volume, 2012-16
Table 22: United States generics market geography segmentation: USD billion, 2016
Table 23: United States generics market value forecast: USD billion, 2016-21
Table 24: United States generics market volume forecast: % of total pharma volume, 2016-21
Table 25: United States size of population (million), 2012-16
Table 26: United States gdp (constant 2005 prices, USD billion), 2012-16
Table 27: United States gdp (current prices, USD billion), 2012-16
Table 28: United States inflation, 2012-16
Table 29: United States consumer price index (absolute), 2012-16
Table 30: United States exchange rate, 2012-15
Table 37: Apotex, Inc.: key facts
Table 38: Mylan N.V.: key facts
Table 39: Mylan N.V.: key financials (USD)
Table 40: Mylan N.V.: key financial ratios
Table 41: Novartis AG: key facts
Table 42: Novartis AG: key financials (USD)
Table 43: Novartis AG: key financial ratios
Table 44: Teva Pharmaceutical Industries Limited: key facts
Table 45: Teva Pharmaceutical Industries Limited: key financials (USD)
Table 46: Teva Pharmaceutical Industries Limited: key financial ratios
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.